HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Online-Only Appendix All Versions of this Article: dc06-1328v1 dc06-1328v2 30/5/1044    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McNally, P. G Articles by Heller, S. R Search for Related Content PubMed PubMed Citation Articles by McNally, P. G Articles by Heller, S. R Social Bookmarking                What's this?

Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes

¹Leicester Royal Infirmary NHS Trust, Leicester, UK
²Bolton Diabetes Centre, Bolton PCT/Bolton Hospitals NHS Trust, Bolton, UK
³Division of Medicine & Therapeutics, Ninewells Hospital, Dundee, Scotland, UK
⁴Wilkinson Associates, Radnage, Bucks, UK
⁵Novo Nordisk Ltd, Broadfield Park, Crawley, West Sussex, UK

s.heller{at}sheffield.ac.uk

ABSTRACT

Objective:Rapid-acting insulin analogs in basal-bolus regimens can reduce nocturnal hypoglycemia, so it is conceivable that twice-daily biphasic insulin analogs might reduce hypoglycemia in patients with insulin-treated type 2 diabetes. We used continuous glucose monitoring (CGMS) and self-reported episodes to investigate differences in the frequency of low glucose values in patients with type 2 diabetes, using either biphasic insulin aspart (BIAsp 30) or biphasic human insulin (BHI 30).

Research Design and Methods:A double-blind, two-period, cross-over trial involving 160 subjects. After 8-weeks' run-in, subjects were randomized to the first of two 16-week treatment periods.

Results:No differences in overall incidence of low interstitial glucose (LIG) were found. 24-h plots of CGMS showed LIG was more frequent at night as during the day, and unrecognized by patients. At night, subjects spent significantly less time (% of total CGMS recorded) with IG <3.5 and <2.5 mmol/l during BIAsp 30 than during BHI 30 treatment (<3.5 mmol/l: 6.36 vs. 7.93% [mean], 0.67 vs. 2.43% [median], respectively, P = 0.018; <2.5 mmol/l: 2.35 vs. 2.86% [mean], 0 vs. 0% [median], P = 0.0467). No treatment difference in HbA_1c was observed.

Conclusions:Overall rates of low glucose over 24 h were not different, but were twice as frequent at night as during the day in individuals with type 2 diabetes. Compared with BHI 30, BIAsp 30 was associated with similar low IG readings over 24 h, but fewer nocturnal episodes and less self-reported nocturnal hypoglycemia.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K. Esposito, M. Ciotola, M. I. Maiorino, R. Gualdiero, B. Schisano, A. Ceriello, F. Beneduce, G. Feola, and D. Giugliano Addition of Neutral Protamine Lispro Insulin or Insulin Glargine to Oral Type 2 Diabetes Regimens for Patients with Suboptimal Glycemic Control: A Randomized Trial Ann Intern Med, October 21, 2008; 149(8): 531 - 539. [Abstract] [Full Text] [PDF]

				R. Qayyum, S. Bolen, N. Maruthur, L. Feldman, L. M. Wilson, S. S. Marinopoulos, P. Ranasinghe, M. Amer, and E. B. Bass Systematic Review: Comparative Effectiveness and Safety of Premixed Insulin Analogues in Type 2 Diabetes Ann Intern Med, October 21, 2008; 149(8): 549 - 559. [Abstract] [Full Text] [PDF]